<b>Background:</b> The combination therapy of BRAF inhibitors (BRAFis) and MEK inhibitors (MEKis) has been approved as a first-line treatment for metastatic melanoma with BRAF V600 mutants. Here, MAP2K7 is linked to metastatic melanoma.